CTOs on the Move

Axovant

www.axovant.com

 
Axovant Sciences is a leading clinical-stage neurology company focused on the treatment of dementia and related neurological disorders. We aspire to lead the way into a new era of progress to protect the fullness of life for people living with neurologic conditions. We see the potential of compelling therapeutic pathways and set our sights high on creating life-changing advancement for millions of people affected by neurologic disorders.
  • Number of Employees: 250-1000
  • Annual Revenue: $50-100 Million
  • www.axovant.com
  • 11 Times Square 33rd Floor
    New York, NY USA 10036
  • Phone: 833.296.8268

Executives

Name Title Contact Details
John Wright
Chief Technology Officer Profile

Similar Companies

Attralus

Amyloid diseases are a diverse group of disorders, characterized by the deposition of amyloid protein fibrils in vital organs and tissues. There are approximately 30 different types of amyloidosis, each resulting from the misfolding and aggregation of a specific protein, and they are all severely debilitating, progressive, and often fatal.

ABS Lifesciences

ABS Lifesciences is a Plainsboro, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Bioneer

Bioneer is a Alameda, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

arizonia infectious disease society

arizonia infectious disease society is a Phoenix, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Appia Bio

Appia Bio is an early stage biotechnology company based in Los Angeles, California. Founded in 2020, Appia Bio is focused on discovering and developing engineered allogeneic cell therapies across a broad array of indications with a scalable technology platform that increases access for patients. With its ACUA (Appia Cells Utilized for Allogeneic) technology platform, Appia Bio leverages the biology of lymphocyte development with chimeric antigen receptor (CAR) and T-cell receptor (TCR) gene engineering to generate CAR-engineered invariant natural killer T (CAR-iNKT) cell subtypes from hematopoietic stem cells (HSCs).